Glutazumab - Gmax Biopharm

Drug Profile

Glutazumab - Gmax Biopharm

Alternative Names: GMA-102

Latest Information Update: 02 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Gmax Biopharm
  • Class Antihyperglycaemics; Monoclonal antibodies
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Type 2 diabetes mellitus

Most Recent Events

  • 30 Oct 2017 Phase-II clinical trials in Type-2 diabetes mellitus in Australia and New Zealand (SC) (Gmax Biopharm pipeline of November 2017) (ACTRN12617000811303)
  • 05 Jun 2017 Gmax Biopharm plans a phase II trial for Type-2 diabetes mellitus in Australia and New Zealand (ACTRN12617000811303p)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top